Nymox Pharmaceutical Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017 - 1997
Net Income	-6.58	-12.54	-11.74	-13.16	-10.59	Upgrade
Depreciation & Amortization	0.25	0.25	0.27	0.57	0	Upgrade
Share-Based Compensation	0.59	2.6	1.75	3.01	3.81	Upgrade
Other Operating Activities	0.53	-0.14	-0.31	2.16	-1.02	Upgrade
Operating Cash Flow	-5.21	-9.82	-10.04	-7.43	-7.8	Upgrade
Capital Expenditures	0	-0.01	-0.01	0	-0.04	Upgrade
Investing Cash Flow	0	-0.01	-0.01	0	-0.04	Upgrade
Share Issuance / Repurchase	6.01	7.28	8.69	5	14.93	Upgrade
Debt Issued / Paid	-0.23	-0.24	-0.27	-0.28	0	Upgrade
Financing Cash Flow	5.78	7.05	8.42	4.72	14.93	Upgrade
Net Cash Flow	0.57	-2.78	-1.63	-2.71	7.1	Upgrade
Free Cash Flow	-5.21	-9.83	-10.05	-7.43	-7.84	Upgrade
Free Cash Flow Margin	-	-	-201000.00%	-6405.17%	-2621.07%	Upgrade
Free Cash Flow Per Share	-0.06	-0.12	-0.14	-0.11	-0.13	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).